Avivagen Inc. (OTCPK: VIVX.F)
Health Care · Pharmaceuticals · CA
$—
— today · — 1Y
Avivagen Inc. (OTCPK: VIVX.F) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $78.00 and employs 13 people.
trading between 0.00 and 0.00.
Tweenvest scores Avivagen Inc. across four factors: quality 4/100, value 43/100, growth 54/100. Its strongest factor is growth.
VIVX.F price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $78.00
- Revenue (TTM)
- $543.72K
- P/E
- —
- EPS
- -0.07
- Dividend yield
- —
- Beta (5Y)
- -16.14
- 52-week high
- $0.00
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 77.69M
- Employees
- 13
- Next earnings
- —
About Avivagen Inc.
Avivagen Inc., a life sciences company, focuses on developing and commercializing products for livestock feeds that support immune function and help animals to achieve their growth and productivity. The company offers OxC-beta Livestock, a premix for inclusion in livestock feeds; Vivamune health chews for dogs; Dr. Tobias dog chews; and Dr. Tobias Beta blend for the human immune system. It serves in the United States, Canada, the Philippines, Taiwan, Thailand, China, Mexico, Brazil, and Malaysia. Avivagen Inc. was incorporated in 2005 and is headquartered in Ottawa, Canada.
- ISIN
- CA05382F2026
- Listed since
- Oct 25, 2007
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,237.51 | -1.43% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $272.29 | +0.76% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $150.48 | -1.36% |
| Roche Holding AGSWX: ROP | $373.91B | CHF369.10 | -1.73% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £120.32 | -1.70% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $27.89 | -0.64% |
Figures last refreshed Aug 18, 2026.